Shareholders Reject Silexion's 175M Share Increase and 1-for-15 Reverse Split
SLXN is trading near its 52-week low of $0.236 (10% above the low) on light trading volume (0.2× avg).
Summary
Shareholders rejected both the 175M share authorization increase and the 1-for-15 reverse split, leaving Silexion without the tools it sought to address its Nasdaq delisting notice and fund its clinical trials.
Key Events · Corporate Governance and Compliance · SLXN
-
Both Proposals Rejected by Shareholders
The 175M share authorization increase received only 24.6% support (536,203 votes for vs 1,645,147 against) and the 1-for-15 reverse split received only 25.9% support (571,411 for vs 1,636,939 against), both failing to reach a simple majority.
-
Nasdaq Delisting Risk Unresolved
The reverse split was intended to lift the share price above Nasdaq's $1.00 minimum bid requirement; its rejection leaves the company's delisting notice from September 25, 2026 unaddressed.
-
Capital Raise Capacity Blocked
The rejected 175M share authorization increase would have expanded authorized shares from 15.9M to 190.9M, enabling future equity raises; without it, the company's ability to fund its Phase 2/3 SIL204 trial is constrained.
-
Quorum Challenges Persist
The meeting was reconvened twice (September 9 to September 16 to September 23) due to lack of quorum, with only 36.8% of outstanding shares represented at the final vote.
Analysis · SLXN · Life Sciences
At the reconvened extraordinary general meeting on September 23, 2026, shareholders voted down both the 175 million share authorization increase and the 1-for-15 reverse split. The authorization increase drew only 24.6% support, while the reverse split managed just 25.9% — each far short of the required simple majority. This outcome is a critical setback for a company already under a Nasdaq delisting notice for its sub-$1.00 share price and facing going-concern doubts. Without the reverse split, the stock remains below the $1.00 minimum bid requirement; without the share authorization increase, the company's ability to raise urgently needed capital for its Phase 2/3 SIL204 pancreatic cancer trial is severely constrained. The company must now either re-propose these measures, find alternative financing, or risk delisting and an inability to fund operations.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 45.4% of the 295 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.24 to $42.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.